															CIC)M	IS I	-0	RM
00												—							
SUSPEC	CT ADVERSE I	REAC	HON REPO	ΚI															
								П				П	T	Т	Т	Τ	Τ		
													丄	\perp	丄	L			
			I RFA	CTION	LINFOR	MATION													
1. PATIENT INITIALS	I. REACTION INFORMATION S 1a. COUNTRY 2. DATE OF BIRTH 2a. AGE 3. SEX 3a. WEIGHT 4-6 REACTION ONSET										SET	8-12	2 C	HEC	K ALL				
(first, last) PRIVACY	PANAMA	Day	Month Year	, 6	Famala	Unk	Day		Month		Year	1			OPRIA				
PRIVACY			PRIVACY	Years	Female				Unk	<u> </u>		4							
7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data) Event Verbatim [LOWER LEVEL TERM] (Related symptoms if any separated by commas)												PATIENT DIED							
painful injection [Injection site pain]											INVOLVED OR								
the medication could not be administered [Drug dose omission by device] injection process was difficult because the pen was not friendly/it is difficult for me to use it [Device difficult to											PROLONGED INPATIENT HOSPITALISATION								
use]																			
the needles of the pen were damaged [Needle issue] the pen turned with difficulty/dosing button was jammed, it did not turned/it doesn't screw it on properly												INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR							
[Device mechanical jam]															PACITY				
80% of the medication was spilled. [Device leakage]																			
the numbers were not visible [Device image display issue] (Continued on Additional Information Page)									Page	, c	그 뉘	IFE HRE	ATENII	NG					
					•						90	<u>′ I</u>							
			II. SUSPEC	T DRU	JG(S) IN	FORMA	MOIT	1				_							
14. SUSPECT DRUG(S) (include generic name) #1) Genotropin Pen (SOMATROPIN) Solution for injection #2) Genotropin Pen (SOMATROPIN (DEVICE CONSTITUENT)) Solution for injection {Lot # A143}											20. DID REACTION ABATE AFTER STOPPING								
												DRUG	3?						
						6. ROUTE(S) OF ADMINISTRATION								/EC	□ NO	<u> </u>	D	^	
#1) 0.8 mg, daily #2)						1) Unknown 2) Unknown							ш,	E9	Пис	ا ر	ΔIN	А	
17. INDICATION(S) FOR	•								21. DID REACTION REAPPEAR AFTER										
#1) Unknown #2) Unknown														DUCTI		?			
). THERAPY DURATION							_		_				
, '						1) Unknown 2) Unknown							YES NO NA						
#2) Unknown #2) Unknown																			
		Ш	CONCOMI	TANT [DRUG(S) AND H	ISTO	DR'	Y										
22. CONCOMITANT DRU	JG(S) AND DATES OF ADM	/INISTRA	TION (exclude those us	sed to treat r	reaction)														
	HISTORY. (e.g. diagnostics			onth of perio															
From/To Dates Type of History / Notes Description Unknown																			
IV. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER 26. REMARKS																			
24a. NAME AND ADDRESS OF MANUFACTURER Pfizer S.A.						ZO. NEWANIO													
Laura Arce Mora Avenida Escazú, T																			
San jose, COSTA																			
	25b. NA	25b. NAME AND ADDRESS OF REPORTER																	
		NAM	NAME AND ADDRESS WITHHELD.																
24c. DATE RECEIVED BY MANUFACTURE	24d. REPOR	T SOURC			NAM	AND ADD	RESS	S WI	THHE	ELD.	•								
	NAM	NAME AND ADDRESS WITHHELD.																	
16-APR-2025	☐ HEALTH PROFE:	I SSIONAL	OTHER: Spont	aneous															
DATE OF THIS REPORT	l <u>—</u>	T TYPE	_																
22-APR-2025	INITIAL		FOLLOWUP:																

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

Case Description: This is a spontaneous report received from a Consumer or other non HCP and a Nurse from product quality group, Program ID: 164974.

A 6-year-old female patient received somatropin (GENOTROPIN PEN), (Batch/Lot number: unknown) at 0.8 mg daily, Device Lot Number: A143, Device Expiration Date: May2025. The patient's relevant medical history and concomitant medications were not reported.

The following information was reported: INJECTION SITE PAIN (non-serious), outcome "unknown", described as "painful injection"; DRUG DOSE OMISSION BY DEVICE (non-serious), outcome "unknown", described as "the medication could not be administered"; DEVICE DIFFICULT TO USE (non-serious), outcome "unknown", described as "injection process was difficult because the pen was not friendly/it is difficult for me to use it"; NEEDLE ISSUE (non-serious), outcome "unknown", described as "the needles of the pen were damaged"; DEVICE MECHANICAL ISSUE (non-serious), outcome "unknown", described as "the pen turned with difficulty/dosing button was jammed, it did not turned/it doesn't screw it on properly"; DEVICE LEAKAGE (non-serious), outcome "unknown", described as "80% of the medication was spilled."; DEVICE INFORMATION OUTPUT ISSUE (non-serious), outcome "unknown", described as "the numbers were not visible". The action taken for somatropin was unknown.

Causality for "painful injection", "the medication could not be administered", "injection process was difficult because the pen was not friendly/it is difficult for me to use it", "the needles of the pen were damaged", "the pen turned with difficulty/dosing button was jammed, it did not turned/it doesn't screw it on properly", "80% of the medication was spilled." and "the numbers were not visible" was determined associated to device constituent of somatropin (malfunction).

Additional information: Reporter stated the needles of the pen were damaged and the medication could not be administered because the pen turned with difficulty and the numbers were not visible, so it was not possible to set the dose. Reporter mentioned that she had two daughters and the injection process was difficult because the pen was not friendly and this led to a painful injection and she did not know if it was because of the pen or a bad administration technique. Reporter also stated that she set the medication and it did not screw correctly so 80% of the medication was spilled. Nurse stated the dosing button was jammed, it did not turned. On 16Apr2025, patient's mother reported that The pen is damaged, it is difficult for her to use it.

Follow-up (16Apr2025): This is a spontaneous follow-up report received from a Consumer or other non-HCP, Program ID: 164974. Updated information included: Reaction data (event Device difficult to use subsumed, verbatim updated); clinical course